Metabolically supported chemotherapy for managing end-stage breast cancer: A complete and durable response
Yükleniyor...
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Breast cancer accounts for significant morbidity and mortality worldwide. Currently, treatment options in
metastatic breast cancer consist of chemotherapy, along with endocrine, radiation, and/or biological
therapies. Although advances in management have improved overall survival times, the treatment options
for women with end-stage disease are mostly limited to supportive care.
Herein, we present a case report that highlights the response of a 47-year-old premenopausal woman with
end-stage (T4N3M1) breast cancer treated with metabolically supported chemotherapy (MSCT), ketogenic
diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT). The patient first noticed a right
breast mass in late 2016, which was initially evaluated and ruled out as a cyst. Skin ulceration was observed
in the region of the suspected cyst in May 2017. Subsequent bilateral breast ultrasound identified masses in
both breasts and an enlarged right axillary lymph node. The diagnosis following biopsy was grade 3,
estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), human epidermal growth factor
receptor 2 negative (HER2-), invasive ductal carcinoma of the breast. Initially, the patient refused to receive
conventional chemotherapy because of its potential for side effects and toxicity, but she sought medical
treatment in August 2018 following extensive disease progression and deterioration of general health. On
reevaluation, the patient was considered ineligible for conventional treatment due to her advanced endstage disease, poor performance status (Eastern Cooperative Oncology Group score: 3), and advanced
respiratory symptoms. Exploring other options, the patient was admitted to the ChemoThermia Oncology
Center, Istanbul, Turkey in November 2018. At that time, the patient weighed 38 kg (body mass index: 18.1
kg/m2
) and had extensive metastatic disease with lesions in the brain, lungs, mediastinum, liver, abdomen,
and bones that were detected by magnetic resonance imaging of the brain (with contrast) and whole-body
(18F)-fluorodeoxyglucose-positron emission tomography-computed tomography. The patient received a sixmonth treatment protocol comprised of MSCT, KD, HT, and HBOT, which eliminated all detectable lesions.
The therapeutic response was sustained for two years with maintenance treatment comprising KD, dietary
supplements, and repurposed medications. This single case report presents evidence of a complete and
durable response to a treatment protocol combining MSCT and a novel metabolic therapy in a patient with
end-stage breast cancer.
Açıklama
Anahtar Kelimeler
Metabolically Supported Chemotherapy, Ketogenic Diet, Hyperthermia, Hyperbaric Oxygen Therapy, Cancer, Warburg Effect, Repurposed Drugs, Cancer As a Metabolic Disease, Ketogenic Metabolic Therapy, End-Stage Breast Cancer
Kaynak
Cureus
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
13
Sayı
4
Künye
İyikesici, M. S., Slocum, A. K., Winters, N., Kalamian, M., & Seyfried, T. N. (2021). Metabolically Supported Chemotherapy for Managing End-Stage Breast Cancer: A Complete and Durable Response. Cureus, 13(4).
